Predialytic treatment of chronic kidney disease by Swanepoel, CR
The predialytic treatment of chronic kidney disease (CKD) begins 
at the time of the diagnosis of the kidney disease.  Once this 
diagnosis is made, the advance towards end-stage kidney failure, 
with consequent death or dialysis therapy, is virtually inexorable in 
the majority of cases.  In a study from Norway, 73% of 3 047 patients 
in stage 3 (see staging below) had a decline in the glomerular 
filtration rate over a 44-month period.1 The decline in females is 
slower (the weaker sex?).
The length of time of this progression to end-stage kidney failure 
is dependent on the underlying kidney disease and the therapeutic 
intervention.  One attempts to slow the progression for as long as 
possible.  Some improve, as seen in the MDRD study2 and above,1 
and many patients die with kidney disease rather than from it.
It must also be apparent that a glomerulonephritis, which is 
secondary to systemic disease, has its course, to a large extent, 
determined by the culprit disease.  A good example of this is 
syphilis. Luetic disease classically produces a membranous 
nephropathy, which in some cases is curable within 24 hours but 
in all cases is curable within approximately 2 weeks with antibiotic 
treatment. Systemic lupus erythematosus (SLE), which has no 
characteristic histological type, may have a rapidly deteriorating 
course, depending on the presence of crescent and necrosis.  The 
NIH studies on long-term SLE therapy showed that the course can 
be favourably influenced by utilising cyclophosphamide. However, 
at present there is no satisfactory treatment for lupus nephritis. 
More recently, the use of mycophenolate mofetil (MMF) has raised 
hopes of an enduring, successful form of less toxic therapy for 
SLE.  Diabetic nephropathy is a condition where tight control of 
blood sugar slows the progression of the nephropathy to end-stage 
kidney failure.3 
There are many causes of CKD and the approach outlined below 
can be applied to all of them.
An idiopathic glomerulonephritis is used as an example below to 
illustrate an approach to the predialytic treatment of CKD. The 
indisputable fact is that there is no definitive therapy per se for 
most of the idiopathic glomerulonephritides.  Immunosuppression 
may or may not have a positive effect.  In a percentage of cases 
of idiopathic membranous glomerulonephritis, spontaneous 
remission occurs.
In Fig. 1, the diagnosis of glomerulonephritis (GN) is made at a 
time when the creatinine clearance is normal.  The patient may 
present for an insurance examination and is then coincidentally 
noted to have proteinuria and haematuria with a renal biopsy 
confirming the clinical impression of an idiopathic GN.  The renal 
function will invariably deteriorate over the ensuing years – in the 
hypothetical case under discussion the number of years shown is 
20 (this would hold true for many of the nephritides).  
In my original description, published 10 years ago,4 I had divided 
the progression into the stages A, B, C, D, E, and F.  Each stage 
merged into the next and represented a continuum in the 
progressive deterioration of the renal function of the index case.  I 
pointed out that each doctor must utilise various treatment options 
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Fig. 1. A hypothetical case showing stages in the progression to end- 
stage kidney disease. Treatment options are proposed at each stage.
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at each stage in an effort to ensure that the 
progression to end-stage renal failure is 
as slow and as symptom free as possible. 
Recently the Kidney Disease Outcomes 
Quality Initiative (KDOQI) guidelines were 
published and incorporated a staging system 
for glomerular filtration rate (GFR).5 I have 
attempted to match these stages of GFR 
with the clinical stages first described in the 
article of 1997 (Table I).  
Clinical stage A 
At this early stage, the serum creatinine 
may be normal and the patient may be 
asymptomatic and, unfortunately in many 
instances, unaware of the disease lurking 
in the kidneys.  Important aspects during 
this stage that will require attention are 
obesity, hypertension and smoking habits. 
An important first-step consideration in 
the management of any glomerulonephritis 
is to reduce weight in the obese patient. In 
patients with renal disease, obesity per se has 
been shown to aggravate hypertension and 
proteinuria.6,7 Reduction of weight in obese 
patients significantly reduces proteinuria.6 
Exercise will aid in weight reduction, but 
there are no convincing studies that exercise 
per se is beneficial in slowing the progression 
of deteriorating renal function.8 It has been 
shown without a satisfactory explanation 
that, paradoxically, being overweight confers 
an advantage for all-cause mortality in 
patients on dialysis. The exact mechanisms 
giving this advantage are uncertain, but 
Malnick and Knobler have derived a list of 
clinical characteristics in the obese patients 
who are at risk.9 The risk factors include all 
features of the metabolic syndrome.
During these early years, clinically classified 
as stage A, maintenance of a normal blood 
pressure must be the main objective for the 
attendant doctor. CKD is a risk factor for 
cardiovascular disease. Early treatment of 
blood pressure and lifestyle changes may 
reduce the incidence of this complication. 
Various studies have shown the important 
benefits to be gained by good blood 
pressure control.  This is also the single most 
important factor in slowing the progression 
to end-stage failure for non-diabetic kidney 
disease.10 Angiotensin-converting enzyme 
inhibitors (ACE-I) and/or angiotensin II 
receptor blockade (ARB) agents must be 
first-line therapy in any patient with kidney 
disease. 
The realisation that there exists an ACE-I 
‘escape’ phenomenon whereby peripheral 
conversion of angiotensinogen and 
angiotensin I takes place, despite ACE-I use, 
is well recognised.  It has, however, been 
found that combining an ACE-I with an 
ARB is of synergistic value and overcomes 
the ‘escape’.   The use of these combinations 
has succeeded in reducing the amount of 
protein lost, particularly in diabetics, more 
than with an ACE-I alone. The ARB studies, 
particularly in type 2 diabetics, make it 
almost mandatory to use an ARB as first-
line treatment in these patients.  
More recently a total blockade of the renin-
angiotensin-aldosterone system (RAAS) 
has been suggested whereby an aldosterone 
antagonist is also prescribed. It was shown 
that spironolactone may reduce proteinuria 
and slow progression in patients with 
CKD.11 Be watchful for the development 
of hyperkalaemia. I have not used an 
aldosterone antagonist in my practice 
and will await positive results from bigger 
efficacy and safety studies before I follow.
The diseased kidney retains salt and water 
and any patient with nephritis should be 
educated to reduce salt intake.  Therefore, 
if the patient is hypertensive, part of the 
antihypertensive therapy must be a diuretic. 
Do not wait for signs of fluid overload 
before prescribing a diuretic; the retained 
fluid may not be clinically detectable early 
in the disease process.  
Various hypertension guidelines have been 
promulgated; the KDOQI guidelines of 2002 
are generally followed and these suggest that 
the blood pressure be maintained below 
130/80. He and Whelton have shown that 
the reduction of systolic blood pressure 
is more important than the reduction in 
diastolic blood pressure in preventing end-
stage kidney failure.12 
Since hypertension may be the early sign 
of an underlying glomerulonephritis, it is 
surprising to learn that clinicians fail to 
recognise early renal disease among patients 
with hypertension.13 Any patient with 
hypertension must be worked-up to exclude 
or prove an underlying glomerulonephritis.
It is also important to recognise that 
smoking is an independent risk factor for 
the development of end-stage kidney disease 
in hypertensive patients.14 There is evidence 
that smoking increases the prevalence 
of microalbuminuria (a marker for the 
development of nephropathy) in insulin–
dependent diabetes.15  
Clinical stage B 
Clinical stage B starts at a time when half of 
the renal function is lost.  The management 
started in stage A continues (as it will 
through to stage F), but perhaps slightly 
more aggressively, with greater attention 
to antihypertensive therapy and ensuring 
compliance with salt restriction.
Clinical stage C 
The beginning of this stage is marked by 
a serum creatinine of 200 µmol/l (which 
translates into a creatinine clearance of 
approximately 30 ml/min).  It was generally 
Various studies have shown the 
important benefits to be gained by good 
blood pressure control.  This is also the 
single most important factor in slowing 
the progression to end-stage failure for 
non-diabetic kidney disease.
An important first-step consideration 
in the management of any 
glomerulonephritis is to reduce weight in 
the obese patient.
Table I. Stages of chronic kidney disease 5
Stage Description  GFR (ml/min/1.73m2) Accompanying   
       clinical stage
1 Kidney damage +  ≥ 90   A   
 normal or      GFR
2 Mild       GFR  60 - 89   A
3 Moderate      GFR  30 - 59   B & C
4 Severe       GFR  15 - 29   C, D & E
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thought that the patient must now be put 
on a reduced protein intake. The protein 
restriction approach is still being debated. 
Those in favour16 of restriction are balanced 
against those who do not believe that protein 
restriction has an influence in halting the 
decline of kidney function.17 The opinion 
among the ‘non-believers’ is that a protein-
restricted diet serves only to alleviate 
symptoms (and the patients should rather 
be on dialysis) and relieve the pruritus (via 
inorganic phosphate depletion).  The work 
of Giovannetti using vegetable protein 
with essential amino-acid supplements has 
not been generally popular. This supple-
mental approach requires total compliance 
with good financial resources. We18 and 
others have shown that not much is to be 
gained by using the very-low-protein diet 
supplemented with essential amino acids.  
In my opinion the majority of our patients 
are undernourished and are financially 
forced to be on a ‘natural’ protein restriction. 
In South Africa, we have no reports of 
benefit derived from protein restriction 
alone. Perhaps in the more affluent patients 
a compromise could be the use of 0.8 g/kg of 
protein per day, of which approximately 85% 
is animal in origin and the rest is made up of 
vegetable protein.  
In patients with type 1 diabetes, there 
is evidence that a low-protein diet 
positively limits the progression of diabetic 
nephropathy.19 The evidence of benefit in type 
2 diabetic nephropathy is contradictory.  This 
may be as a consequence of the associated 
vascular disease morbidity, which is such a 
predominant feature in type 2 diabetics.  
At this fairly advanced clinical stage of 
renal failure, the renal preserve depends 
on the maintenance of perfusion and any 
disruption of its regulation will cause the 
filtration pressure, and consequently the 
creatinine clearance, to drop. Therefore the 
use of certain drugs, e.g. non-steroidal anti-
inflammatory drugs (NSAIDs), and excessive 
use of diuretics must be monitored carefully. 
The use of an ACE-I or ARBs in patients 
with severe peripheral vascular disease (and 
therefore, by extrapolation, main and/or 
smaller renal artery atherosclerosis) will 
cause an already compromised glomerular 
perfusion to fall further.  
I show Fig. 2 out of interest.  It demonstrates 
the hyalinosis found in the afferent arteriole 
of a patient with diabetes.  Note the marked 
narrowing of the lumen.  If this degree 
of hyalinosis extended throughout the 
kidney, as is possible in advanced diabetic 
nephropathy, then it may give rise to a 
situation similar to that of renal artery 
stenosis.  
I suggest that whenever an ACE-I or 
ARB is used (and they must be used 
whenever possible) with advanced diabetic 
nephropathy, the serum creatinine be 
measured 3 - 5 days after starting treatment 
(as well as the potassium).  Any unexplained 
increase in the serum creatinine level must 
compel one to stop the ACE-I or ARB. 
Similarly, if a diabetic patient with advanced 
CKD has been on treatment with either 
an ACE-I and/or an ARB and there is an 
unexplained deterioration in renal function, 
consider that decreased glomerular 
perfusion may be one of the causes. One may 
wish to stop the ACE-I or ARB temporarily 
and repeat the creatinine measurement. 
Obviously renal artery stenosis must always 
be excluded in these situations.
An important point is that NSAIDs, by 
inhibiting prostaglandin synthesis, produce 
a state of diuretic resistance.
Clinical stage D 
According to the KDOQI staging of 
kidney disease, this is still stage 4.  My 
original reason for splitting the creatinine 
clearance between 20 - 30 ml/min into 2 was 
because I believe this period is extremely 
important. It requires much attention to 
detail.  This clinical stage D is at a creatinine 
clearance of approximately 20 - 25 ml/
min and has important implications for 
the practitioner.  The treatment begun in 
clinical  stages A, B and C continues.  In 
stage D, the functioning renal mass has 
been reduced considerably and it is unable 
to maintain the successful excretion of 
inorganic phosphate, with the consequent 
development of hyperphosphataemia.  In 
addition, the kidney’s ability to further 
hydroxylate hydroxy25-D3 is impaired. 
Both the hyperphosphataemia and the 
diminished production of vitamin D3 result 
in hypocalcaemia and the excessive secretion 
of parathyroid hormone (PTH).  
The abnormal blood biochemistry, elevated 
inorganic phosphate and PTH levels may 
occur at earlier stages. The approach to 
the treatment of these abnormalities at an 
earlier stage is uncertain. There are cost 
implications, as well as exposure to excessive 
calcium, in designing the treatment strategy. 
Which CKD patient would wish to take 
calcium carbonate for many years and risk 
the exposure to excessive calcium with 
the possibility of vascular calcification a 
looming threat?  The decision to treat this 
biochemical abnormality at an earlier stage 
must be individualised. The treatment 
programme must include one of the newer 
In patients with 
type 1 diabetes, 







Fig. 2. An afferent arteriole in the kidney of a diabetic patient. The arrow points to an almost 
absent lumen which has been obliterated by extensive hyalinosis. 
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calcium-free phosphate binders mentioned 
below.
The effect of this abnormal physiology 
results in a bone mineral disorder. The ‘new’ 
terminology is chronic kidney disease–
bone mineral disorder (CKD-BMD). 
Only when a bone specimen is examined 
by histomorphometry, is the term renal 
osteodystrophy used.
Renal osteodystrophy is further classified in-
to states of T (turnover), M (mineralisation) 
and V (volume). Clinically it is easy to 
recognise a high turnover state, i.e. osteitis 
fibrosa cystica, diagnosed by the classic 
X-ray appearances (Fig. 3) as well as the 
low turnover bone state, i.e. osteomalacia 
and adynamic bone disease. With the 
TMV classification, the old histological 
terminology, e.g. osteitis fibrosa cystica, will 
disappear from use.
The high turnover states have high bone 
volumes and the low turnover states low 
volumes.  A proportion of patients may have 
a mixed picture.  Earlier studies showed that 
adynamic bone disease (a very low turnover 
state) occurs commonly in predialysis 
patients and diabetics.20 It is important 
to realise that at the early stages the bone 
disease is unusually asymptomatic. 
The treatment is to decrease the phosphate 
level in the blood and supply calcium.  This 
is achievable by using calcium carbonate or 
calcium acetate, taken a few minutes before 
each meal.21 The fall in the phosphate level 
and the supply of calcium will suppress PTH 
secretion and prevent the development of 
renal osteodystrophy.  However, if the PTH 
level is suppressed too vigorously, then 
low turnover bone disease will develop. 
This is because the PTH receptors, in this 
predialysis period, are less responsive to 
parathyroid hormone. Therefore it is not 
advisable to lower the PTH levels within the 
normal range.  Conversely, very high PTH 
levels are associated with high turnover 
disease.  The recommendation is to keep the 
PTH levels approximately 2 - 3 times above 
the normal level.  
There have been recent concerns about 
the assay used to measure PTH. Currently 
the intact assay is used; it includes in the 
measurement those ‘bits’ of PTH that are 
inactive and inhibitory.  So, a very high PTH 
level, as measured by the intact method, 
may not represent an active hormone and 
consequently not a high turnover bone state. 
It is for this reason that the examination of 
bone histology becomes important. 
Aluminium hydroxide is the most effective 
phosphate binder in use.21 The deleterious 
effects of aluminium deposited in body 
tissues and the calcification front in the 
bones is well known.  Therefore if aluminium 
hydroxide is required (e.g. in those who 
are particularly unresponsive to calcium 
carbonate, i.e. hyperphosphataemia persists) 
then it should be used for short periods only. 
Aluminium deposition, at the calcification 
front, results in the development of low 
turnover bone disease.
There are newer agents on the market 
that are not calcium based. They are lant-
hanum carbonate (Fosrenol) and sevelamer 
(Renagel).  The cost of these is extravagant 
and prohibits their use in the state sector. In a 
comparative study, the CARE study, calcium 
acetate was superior to sevelemar in reducing 
phosphate levels.22 Any calcium-containing 
phosphate binder is contraindicated in the 
presence of hypercalcaemia.
Vitamin D3 plays an important role in 
the remodelling process of the bone. If 
the serum calcium does not recover with 
calcium carbonate use, then, provided 
the phosphate level has been controlled, 
vitamin D3 must be prescribed. Excessive 
doses of vitamin D3 may result in excessive 
suppression of PTH secretion, hyper-
calcaemia and the development of the low 
turnover bone diseases. An important 
consideration is to maintain the product 
of calcium and inorganic phosphate below 
4.0 mmol/l.  Above a value of 4.0, the 
calcium phosphate may no longer be held in 
solution and it will deposit out into various 
tissues, i.e. metastatic calcification occurs. 
A form of metastatic calcification, where 
calcium is deposited in the walls of small 
arterioles, called calciphylaxis, may also 
occur in a milieu of secondary/autonomous 
hyperparathyroidism. It is far more com-
mon in those patients on dialysis and in 
the post-transplant period but may have its 
‘beginnings’ in the predialysis period.  The 
patient presents with skin infarcts or, as 
a prelude to the skin infarcts, with livedo 
reticularis (Fig. 4).  The progression of the 
disease may be halted by parathyroidectomy 
or may continue relentlessly with massive 
Fig. 3. X-ray of the pelvis in a patient with CKD. The arrow points to periosteal resorption as occurs 
in high turnover bone disease. Note the poor outline of the femurs.
Fig. 4. Severe calciphylaxis in a patient with CKD. Note the extensive skin and subcutaneous infarc-
tion with underlying muscle clearly visible.
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skin necrosis and ultimate death from 
sepsis (as occurred with the patient in the 
photograph).
A fall in haemoglobin usually occurs at 
the end of this stage, but with the advent 
of recombinant human erythropoietin 
(EPO), this can easily be treated. The 
EPO does not have a negative or positive 
influence on the progression to end-stage 
kidney disease.  It does improve the quality 
of life. 
Clinical stage E
Treatment begun in the earlier stages 
continues.  Urine output begins to fall 
and far more aggressive diuretic and 
antihypertensive therapy may be required. 
Electrolyte disorders on a normal diet 
may occur.  The most lethal electrolyte 
disorder is that of hyperkalaemia (usually 
when urine output falls to less than 1 litre 
per day) and the patient must be advised 
on the appropriate diet.  The main culprit 
foods are citrus fruits, tomatoes, bananas 
and avocado pears.
Clinical stage F
This is end-stage renal failure and the form 
of the future maintenance dialysis therapy 
needs to be planned, i.e. haemodialysis or 
continuous ambulatory peritoneal dialysis 
(CAPD). A Tenckhoff catheter for CAPD 
can be inserted a week before use, although 
laparoscopic techniques allow for earlier 
(almost immediate) use. If haemodialysis 
is the best choice for a patient, then early 
creation of an arteriovenous fistula must 
be undertaken for access to the dialysis 
machine.  Such early preparation is vital 
since it takes approximately 6 weeks for 
the fistula to ‘mature’ before being used.  
Sepsis is a major problem with emergency 
push-in dialysis catheters (either internal 
jugular vein, which is preferred, or femoral 
vein).  The advent of more permanent 
tunnelled access, inserted by a surgeon, has 
to a large extent circumvented the sepsis 
problem. The application of mupirocin 
(Bactroban) ointment to the exit site is now 
mandatory and has reduced serious exit-
site sepsis.  The ointment is applied in the 
dialysis centres after each dialysis session. 
Unfortunately, costs have consequently 
increased, since the catheters, theatre-time, 
surgeon and anaesthetist are expensive.
Early referral to a registered nephrologist 
is therefore very important. A group of 
investigators has shown that in those 
patients who died within 1 year of starting 
dialysis, when compared with those who 
survived longer than 1 year, the interval 
between first presentation and dialysis 
was shorter in the death group. Plasma 
urea and creatinine were also greater at 
presentation in the group that died.23 So 
share the management of these complex 
patients with your friendly nephrologist. 
The dyslipidaemia of 
CKD 
The results of investigations on the 
influence of the abnormal lipid metabolism 
on progression in CKD have to date been 
unhelpful. There are many short-term 
studies, with few patients, which have 
shown variable results.  The outcome of 
a clinical study in our unit showed that, 
by using a HMGCoA reductase inhibitor 
in a group with idiopathic membranous 
nephropathy, proteinuria was markedly 
decreased. In this small study, no 
influence on the creatinine clearance was 
shown.24 However, until bigger studies 
are available and there are no contra-
indications to the use of lipid-lowering 
agents, I recommended their use, not only 
to attempt to slow progression, but also to 
treat the dyslipidaemia. This is particularly 
relevant in the nephrotic syndrome where 
there is a major lipid abnormality.
Urinary tract infec tions
Clearly another self-explanatory step in 
the slowing of progression relates to the 
treatment and prevention of urinary tract 
infections. Long-term prophylaxis must 
also be employed in those with surgically 
uncorrectable ureteric reflux and renal 
calculi as well as those with repeated 
infections from bladder diverticulae or 
indwelling catheters (long-term use in 
those with spinal injuries).
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In a nutshell 
•    Progression of renal function deterioration occurs in the majority of patients with CKD.
•    The progression can be slowed by paying particular attention to blood pressure control and, additionally in diabetic nephropathy, tight 
control of blood sugar. 
•    Obesity and smoking are deleterious factors in progression and must be handled from the outset.
•    Salt retention is always a problem with the diseased kidney and therefore salt restriction and a diuretic are useful in alleviating fluid 
retention and controlling the blood pressure.
•    ACE-I and/or ARB treatment is essential in any patient with CKD with proteinuria and/or hypertension.  They have a positive influence 
in slowing renal function deterioration. 
•    NSAIDs inhibit diuretic action.
•    Spironolactone is being suggested for use in patients with CKD accomplishing total RAAS block.  The evidence of efficacy in slowing 
progression and reducing proteinuria is encouraging but not substantial. Judgement on the safe use of this agent is still awaited.
•    Reduction of phosphate levels is essential for the bone well-being of the patient with CKD. The only way we in SA can achieve this is 
with the use of calcium carbonate given before meals. 
•    The new osteodystrophy classification relies on states of bone turnover together with mineralisation status and bone volume.
•    Lipid-lowering agents should be prescribed in patients with CKD (insulin-resistant state) although the efficacy in slowing progression 
has not yet been established. This is particularly pertinent in patients with the nephrotic syndrome. 
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Superwater strikes down bugs
The developers of a form of  ‘super-oxidised’ water claim that their discovery can kill harmful bacteria, fungi and viruses in wounds. The 
new water may be more effective than bleach and not harm human tissue.
The product, called Microcyn, was presented recently at a biomedical business conference in Monaco. The developers said that the 
wounds of diabetic patients treated with the product and an antibiotic healed within 43 days on average, compared with 55 days for 
patients given the standard treatment of iodine plus an antibiotic.
The key ingredients are oxchlorine ions. These ions rapidly pierce the walls of free-living micro-organisms and so kill them. Human cells 
are not affected because they are tightly bound together in a matrix. Microcyn only kills cells that it can completely surround, according 
to researchers. 
New Scientist, 26 May 2007.
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